April 9, 2026 — Gilead Sciences, Inc. (NASDAQ: GILD) has announced a definitive agreement to acquire Munich-based Tubulis GmbH, a next-generation antibody-drug conjugate (ADC) specialist, for approximately $5 billion. The transaction, expected to close in Q3 2026, underscores the pharmaceutical industry's intensifying focus on ADCs as a cornerstone of modern oncology treatment.
Antibody-drug conjugates combine the targeting specificity of monoclonal antibodies with the potency of cytotoxic payloads, enabling selective delivery of cancer-killing agents directly to tumor cells. The ADC market is projected to exceed $30 billion by 2030, driven by the commercial success of products like Daiichi Sankyo's Enhertu and Pfizer's Adcetris.
Tubulis has developed proprietary ADC technology that addresses key limitations of first-generation conjugates:
Novel linker chemistry: Improved payload stability in circulation with efficient release in tumor microenvironment
Site-specific conjugation: Homogeneous ADC products with consistent drug-to-antibody ratios
Optimized payloads: Proprietary cytotoxic agents with improved therapeutic windows
The company's lead candidate, TUB-040, is currently in Phase II trials for NSCLC with promising efficacy signals in checkpoint inhibitor-refractory patients.
Gilead's acquisition signals continued confidence in the ADC platform, driving demand for specialized API manufacturing capabilities including antibody production, linker chemistry, conjugation services, and fill-finish operations. CDMOs with ADC expertise stand to benefit significantly from this market expansion.
Gilead will acquire all outstanding Tubulis shares for $5 billion in cash, funded through a combination of cash on hand and debt financing. Goldman Sachs and Sullivan & Cromwell are advising Gilead; J.P. Morgan and Goodwin Procter are advising Tubulis.
